Luminex Corporation (LMNX) |
|
Price: $0.0000
$0.00
%
|
Day's High:
| 0.00
| Week Perf:
|
|
Day's Low: |
$ 0.00 |
30 Day Perf: |
|
Volume (M): |
0 |
52 Wk High: |
$ 0.00 |
Volume (M$): |
$ 0 |
52 Wk Avg: |
$0.00 |
Open: |
$0.00 |
52 Wk Low: |
$0.00 |
|
|
Market Capitalization (Millions $) |
- |
Shares
Outstanding (Millions) |
47 |
Employees |
1,150 |
Revenues (TTM) (Millions $) |
457 |
Net Income (TTM) (Millions $) |
60 |
Cash Flow (TTM) (Millions $) |
210 |
Capital Exp. (TTM) (Millions $) |
38 |
Luminex Corporation
Luminex Corporation is an American company that is headquartered in Austin, Texas. It was founded in 1995 and has since become a global leader in clinical diagnostics and life science research. The company develops and manufactures innovative instruments, assays, and software solutions that help healthcare providers and researchers identify illnesses, develop new drugs, and improve patient outcomes.
One of the most notable products developed by Luminex Corporation is the xMAP technology, which stands for "multiplex analysis." This technology is a patented multiplexing platform that enables the simultaneous detection of multiple analytes in a single sample. The xMAP technology is used in multiple assays, including infectious disease testing, genetic research, and cancer diagnosis.
Luminex Corporation is divided into two main divisions: the Life Science division and the Clinical Diagnostics division. The Life Science division provides research tools and solutions to academic and commercial research customers, while the Clinical Diagnostics division develops and markets clinical diagnostic assays and systems to healthcare providers.
The company has a global reach, with offices and operations in North America, Europe, Asia, and Australia. It has over 1,200 employees worldwide, and its products have been adopted by thousands of research institutions, clinical laboratories, and healthcare providers.
Luminex Corporation has been recognized for its innovation, quality, and commitment to patient care. It has won multiple awards, including the Frost & Sullivan Technology Innovation Award, the R&D 100 Award, and the William B. Bonifield Award for Innovation. The company is also certified to ISO 9001 and ISO 13485 quality management standards.
Overall, Luminex Corporation is a leading provider of innovative diagnostic and research tools that have helped advance healthcare globally.
Company Address: 12212 Technology Blvd., Austin, 78727 TX
Company Phone Number: 219-8020 Stock Exchange / Ticker: NASDAQ LMNX
|
|
|
|
|
Stock Performances by Major Competitors |
|
|
Co Diagnostics Inc
Co Diagnostics Inc Announces Strong Revenue Growth and Declining Inventories Salt Lake City, March 14, 2024 - Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company, has reported its financial results for the full year ended December 31, 2023. The company's revenue for the fourth quarter of 2023 showed a remarkable growth of 140.476% year on year, amounting to $3.37 million. However, they experienced a loss of $-0.50 per share during this period. In comparison to other companies in the Medical Equipment and Supplies sector, Co Diagnostics Inc exhibited higher revenue growth. While the overall sector saw a revenue growth of 6.78% in the fourth quarter of 2023 relative to the same period a year ago, Co Diagnostics Inc surpassed this with its substantial increase.
|
Nephros Inc
As a Wall Street journalist, it is important to analyze the financial performance of companies like Nephros Inc in order to provide valuable insights to investors. For the fiscal fourth quarter of 2023, Nephros Inc reported a loss of $0.06 per share, which was an improvement from the loss of $0.16 per share in the same period a year prior. However, compared to the previous financial reporting period, the company's loss per share increased from $0.02. Despite the mixed results in terms of earnings, Nephros Inc saw a significant increase in revenue, with a growth rate of 67.971% to $3.44 million from $2.05 million in the same period last year. The company also reported a net loss of $0.654 million for the fiscal fourth quarter of 2023, compared to a loss of $1.527 million in the same period a year ago. While Nephros Inc's stockpiles increased to $2.5 million, it is worth noting that this level remains below the previous year's level of $3.2 million. The build-up in accounts receivable is a positive sign of rising demand, with accounts receivable valued at $1.5 million, higher than in the preceding quarter. Looking at the full-year results for 2023, Nephros Inc reported revenue of $13.41 million and a net loss of $1.58 million. The company managed to decrease its loss per share to $0.15 from $0.73 in the previous fiscal year, while revenue surged by 34.39% from $9.98 million a year prior.
|
Non Invasive Monitoring Systems Inc
The Medical Equipment and Supplies sector has been closely monitoring the performance of Non Invasive Monitoring Systems Inc as it enters the second quarter of 2024. The company has reported an operating loss of $-0.04 million for the period of November to January 31, 2024, with no mention of revenue figures thus far. This lack of revenue has raised concerns among sector contributors who are looking for signs of growth and financial stability. The Chief Financial Officer of Non Invasive Monitoring Systems Inc is actively pursuing various business strategies in an effort to expand the company's product line and increase profitability. However, the company continues to struggle, reporting a net loss of $-0.054 million for the same period. This represents an increase from the net loss of $-0.048 million reported during the similar period a year ago.
|
Anika Therapeutics Inc
In the dynamic world of the stock market, it is crucial for investors to stay informed about the financial performance and significant developments of companies. Anika Therapeutics Inc., a global joint preservation company in early intervention orthopedics, recently reported its financial results for the October to December 31, 2023, financial period. This article will highlight key observations from the company's financial report and analyze the impact of stock inducement grants on its current share structure and stock price. Financial Performance Overview: During the October to December 2023 financial period, Anika Therapeutics Inc. witnessed a significant increase in revenue, reaching $43.25 million, representing a growth of 9.151% year-on-year. In comparison to its contemporaries in the Medical Equipment and Supplies sector, Anika Therapeutics Inc.'s top-line growth outpaced the industry average, highlighting its strong market position.
|
Cytosorbents Corporation
CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies, has reported its financial performance for the fiscal period between October and December 31, 2023. While the company faced some challenges during this period, it also made significant progress and achieved notable accomplishments in the medical equipment and supplies sector. Financial Performance Summary During the mentioned fiscal span, Cytosorbents Corporation experienced a widening of diminishing returns, with a decrease of $0.12 per share compared to $0.02 a year ago. However, the company managed to improve its EPS from -$0.21 per share in the previous reporting season. Revenue declined by 15.714% to $7.91 million from $9.39 million in the same reporting season a year ago. Sequentially, revenue also deteriorated by 8.04% from $8.61 million.
|
Per Share |
Current |
Earnings (TTM) |
0.8 $ |
Revenues (TTM) |
9.79 $
|
Cash Flow (TTM) |
4.49 $ |
Cash |
-
|
Book Value |
-
|
Dividend (TTM) |
0.41 $ |
|
Per Share |
|
Earnings (TTM) |
0.8 $
|
Revenues (TTM) |
9.79 $ |
Cash Flow (TTM) |
4.49 $ |
Cash |
-
|
Book Value |
- |
Dividend (TTM) |
0.41 $ |
|
|
|
|